

Dual Antiplatelet (DAPT) Switching

Intensification from clopidogrel to ticagrelor	De-escalation from ticagrelor to clopidogrel
<p>In patients:</p> <ul style="list-style-type: none"> - With ACS, who are initially treated with clopidogrel at presentation - Admitted with thrombotic event (e.g. stent thrombosis or ACS), who have been treated with clopidogrel - Who are known poor metabolizer of clopidogrel (e.g., CYP2C19 loss-of-function) 	<p>In patients with:</p> <ul style="list-style-type: none"> - Major bleeding complication that has resolved, who have additional high-risk clinical or angiographic features for thrombotic events, warranting completion of the prescribed course of DAPT - Clinically relevant nuisance bleeding that interferes with patient's ability to continue ticagrelor - Intolerance or side effects to ticagrelor in patients who do not have additional high-risk clinical or angiographic features for thrombotic events - A new indication for requiring concurrent treatment with an oral anticoagulant
<p>Loading Dose: 180 mg PO x 1 Maintenance Dose: 90 mg PO twice daily Timing: Regardless of the timing of the last clopidogrel dose</p>	<p>Loading Dose: Optional 300 mg (–600 mg*) PO x 1 Maintenance Dose: 75 mg PO once daily Timing: At next scheduled ticagrelor dose[†]</p> <p>*Short term (48 hours) pharmacodynamics advantage, might be relevant in early post-ACS/PCI period, if no bleeding risk [†]Extending to 24 hours post last ticagrelor dose may also be reasonable</p>

High-risk clinical and angiographic features for thrombotic events: *Clinical:* Before MI or troponin-positive ACS, DM treated with oral hypoglycemic or insulin, CKD (CrCl \leq 60 mL/min), previous stent thrombosis, current smoker; *Angiographic:* Multiple stents (\geq 3 stents implanted, \geq 3 lesions stented) or use of a biodegradable vascular scaffold, Long lesion length (>60 mm total stent length), complex lesions (bifurcation treated with 2 stents, stenting of chronic occlusion), left main or proximal LAD stenting, multivessel PCI

If switching between ticagrelor and prasugrel, refer to pages 221 and 222 of the [2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy](#).